Harvey Friedman
Infectious Disease · Philadelphia, PANPI 1447282728
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,280 of the $4,233 with a category attached, or 77.5%. Gilead accounts for 92.4% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $3,912 and has fallen 97.0% since, to $117 in 2023.
Across 9 payments — averaging $470.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- Biontech SE$320
Across 590 payments — averaging $3905.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biontech SE$1.7M
- Shionogi Inc$590K
What the payments were for
- Consulting fees$3,28077%
- Travel & lodging$51312%
- Food & beverage$44010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 4 | $3,912 |
| Biontech SE | 5 | $320 |
How this compares
$4,233 in reported general payments places this provider in the 85th percentile of 457 infectious disease providers in Pennsylvania.
Other infectious disease in Philadelphia
- David HornPhiladelphia$2.1M
- Judith WolfPhiladelphia$1.2M
- Karam MounzerPhiladelphia$712K
- William ShortPhiladelphia$520K
- Pablo TebasPhiladelphia$160K
- Lisa SpacekPhiladelphia$131K
- Ian FrankPhiladelphia$112K
- Jay KostmanPhiladelphia$77K
- Ramon GadeaPhiladelphia$55K
- Vincent LorePhiladelphia$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.